As of Oct 21
| +0.46 / +1.12%|
The 32 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 52.35, with a high estimate of 67.76 and a low estimate of 40.56. The median estimate represents a +26.14% increase from the last price of 41.50.
The current consensus among 32 polled investment analysts is to Hold stock in Novo Nordisk. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.